''The market does trust NRT's technology but have risk-rated it due to its early stage of development''
Fully agree Montrachet that the drugs are at an early stage of development and NRT still need to complete further pre clinical Toxicology programs before human clinical trials are approved within the next 12 months or more
The toxicology programs are the most crucial step as these programs will study the adverse affects of the drugs on each person..
Announcement 16/7/2015
''Once the company has completed its pre-clinical toxicology program for Anisina, the drug is expected to enter the clinic for adults in mid-2016 with clinical trials in childhood cancer in Australia and the United States to follow in early 2017.''
Announcement 14/7/2015
''Given the encouraging data from in vitro and in vivo pre-clinical Proof-of-Concept studies in the field of Oncology, our immediate focus is to bring our lead Oncology drug candidates Cantrixil, Anisina and Trilexium into the clinic in 2016 pending successful completion of their respective toxicology programs.''
NRT Price at posting:
23.5¢ Sentiment: Hold Disclosure: Held
